Avigen Inc., of Alameda, Calif., exclusively licensed from the Children's Hospital of Philadelphia technology and know-how from a patent application relating to Factor IX gene therapy using adeno-associated virus. Scientists at the company and hospital developed the technology.

Celtrix Pharmaceuticals Inc., of San Jose, Calif., said it was notified by The Nasdaq-Amex Market Group that its stock will be moved from the Nasdaq National Market to the Nasdaq Small Cap Market effective July 8.

Genentech Inc., of South San Francisco, said underwriters for the upcoming offering by parent company Hoffmann-La Roche Inc., of Nutley, N.J., of Genentech stock have reserved shares for sale to former non-institutional Genentech shareholders. A limited number of shares will be offered at the initial offering price, which is expected to be between $85 and $95 per share.

Human Genome Sciences Inc., of Rockville, Md., reported discovery of a novel immune stimulant that may have significance in treating infectious disease, and may contribute to treatment of immune deficiency disorders as well as certain types of leukemia and lymphomas. The stimulant, B Lymphocyte Stimulator, or BlyS, is a natural component of the immune system. The discovery is reported in the July 9 issue of Science.

Igen International Inc., of Gaithersburg, Md., established three separate business units around its Origen technology. The units are Life Science, Medical and Industrial and address diagnostic and testing markets. They were established to provide product focus, establish greater visibility and growth for shareholders, and provide independent financing options for each unit.

Protein Sciences Corp., of Meriden, Conn., and the Texas A&M University System in College Station signed a definitive agreement to combine their intellectual property and know-how regarding the baculovirus expression vector system. Protein Sciences is exclusively authorized to sublicense the technology.

SciClone Pharmaceuticals Inc., of San Mateo, Calif., said its product, Zadaxin, when administered with 5-FU and interleukin-2, reduced the spread of colorectal cancer and increased survival in an animal model. The combination also stimulated increased production and activation of helper and killer T cells, according to a paper in the current issue of Cancer Immunology and Immunotherapy.